Skip to content
Surf Wiki
Save to docs
general/alpha-1-blockers

From Surf Wiki (app.surf) — the open knowledge base

Buflomedil


Buflomedil, sold under the brand name Loftyl, is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States.

Toxicity

This drug has been suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity. In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options". The European Commission advised all member states to revoke marketing authorisation.

Various adverse effects have been reported to the FDA.

Synthesis

Acylation between 1,3,5-trimethoxybenzene [621-23-8] (1) and 4-pyrrolidinobutyronitrile [35543-25-0] (2) occurs in chlorobenzene solvent in the presence of gaseous hydrochloric acid to give Bufomedil (3). This is a demonstration of the Hoesch reaction.

References

References

  1. "Buflomedil-Containing Drugs May Be Suspended in EU". Medscape.
  2. link. (23 January 2012)
  3. (February 2012). "Buflomedil durchf beschluss".
  4. "Drug cite".
  5. DE2122144 idem Louis Lafon, {{US patent. 3895030 (1975 to Orsymonde);
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

Want to explore this topic further?

Ask Mako anything about Buflomedil — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report